Aurobindo Pharma’s revenue from operations reached ₹102.63 billion in the three months ended Sept. 30, 2026, a 23.9% annual increase and a new quarterly high, as consolidated profit after tax rose 32.5%. The company’s unaudited results cover the second quarter of fiscal 2027.
Revenue was ₹82.86 billion in the year-earlier quarter. Consolidated profit after tax totaled ₹11.24 billion, compared with ₹8.48 billion a year earlier, according to the exchange-filed results.
The filing separately lists ₹11.26 billion in profit after tax attributable to owners of the parent, up 32.7% from ₹8.48 billion. The two figures reflect different reported measures: one is consolidated profit after tax, and the other is the portion attributed to parent owners.
Earnings before interest, taxes, depreciation and amortization (EBITDA) before foreign exchange and other income rose 28.5% to ₹21.56 billion. The EBITDA margin increased to 21% from 20.3%, a 75-basis-point rise, the company reported.
U.S. revenue grew 25% to ₹45.55 billion, Europe revenue increased 27% to ₹31.61 billion, and Growth Markets revenue advanced 16% to ₹10.26 billion. The U.S. was the largest of those three reported markets by revenue. Aurobindo credited gains across its businesses for the quarterly sales high.
The board approved an interim dividend of ₹7 for each ₹1 equity share. Shareholders on the Nov. 11 record date are due to receive payment on or before Nov. 20.
Aurobindo scheduled an earnings call to discuss the results for Nov. 4 at 10 p.m. ET (3 a.m. UTC Nov. 5; 8:30 a.m. IST).
